AntiCancer to test its methioninase as a new treatment for coronavirus
Category: #health  By Mateen Dalal  Date: 2020-02-04
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

AntiCancer to test its methioninase as a new treatment for coronavirus

The threat of coronavirus needs to be addressed as early as possible, particularly since there are no particular treatments or vaccines currently available for patients suffering from coronavirus globally. As the count of patients infected by the 2019-nCoV reaches 10,000 and death toll hits the 200 mark, with both these numbers rapidly growing, without any particular vaccination for at least one year, the situation is turning dire.

AntiCancer Inc, a US-based biopharmaceutical company, reportedly announced its plans to test its methionine as a treatment for the Coronavirus, the current outbreak of the disease is widely spreading across China and steadily making its way around the world.

AntiCancer’s oral recombinant methioninase specifically targets circulating methionine in the patient’s body. Methionine is a type of amino acid that is derived from food that is rich in protein. Oral methioninase has proven to be highly capable of treating cancer, diabetes, and obesity by limiting methionine in the body.

It is proved that virally infected cells are destroyed by methionine restriction. More importantly, coronaviruses have a particular requirement for methionine to replicate and be able to evade the host’s immune system.

Methioninase project leader at AntiCancer, Dr. Qinghong Han stated that oral recombinant methioninase has the capability to reduce or arrest infection of coronavirus (2019-nCoV) in patients, without and with symptoms.

Han further added that the company would first test methioninase with cultured lung cells that are infected by the 2019-nCoV in vitro. After this, the second test would assess the oral recombinant methioninase in patients infected by the virus.

AntiCancer would conduct all these trials in China together with appropriate organizations as well as safety profiles. Oral recombinant methioninase would be an effective treatment for 2019-nCoV disease as coronaviruses also have a special demand for methionine, Han added.

AntiCancer would partner with AntiCancer Beijing, its sister company located in Beijing, in order to develop oral recombinant methioninase for coronavirus (2019-nCoV) in China. AntiCancer is a San Diego based company and its subsidiaries are in Seoul, Tokyo, Nanjing, and Beijing.

 

Source credit: https://www.streetinsider.com/Business+Wire/AntiCancer+Inc.+to+Target+Its+Oral+Recombinant+Methioninase+Against+2019-nCoV+Coronavirus/16402763.htm

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

Facebook testing new option for cross-posting content to Instagram

Facebook testing new option for cross-posting content to Instagram

By Mateen Dalal

Facebook, Inc is reportedly testing an option that will allow users to cross-post their photos, videos, and other posts on their Instagram. It already has the feature to let people cross-post their Instagram content to Facebook. This upcoming featur...

General Motors to recoup USD 1.9 Bn from LG spent on Bolt EV recall

General Motors to recoup USD 1.9 Bn from LG spent on Bolt EV recall

By Mateen Dalal

GM will recover almost all the costs from the recall of its Bolt EV models. Despite the EV battery manufacturing mishap from LG, the two companies will continue to work together. General Motors (GM) has agreed to recover around USD 1.9 billion f...

Tata Motors records 25% jump in global sales in second quarter of 2021

Tata Motors records 25% jump in global sales in second quarter of 2021

By Mateen Dalal

The automaker’s annual wholesale growth has been around 24%. The company saw a 10% rise in passenger car sales during Q2 2021, as compared to the same period in 2020. Tata Motors Limited reported substantial growth in Q2 2021, with its glo...